Here are five things to know:
1. SANUWAVE anticipates sales of more than $500,000 within the next three years of the partnership.
2. The distribution agreement has a maximum value of $3 million.
3. Taiwan represents the company’s second market presence in Asia.
4. LITHOMED predicts SANUWAVE’s orthoPACE device, equipped with patented focused shock wave technology, will do well in the Taiwanese market.
5. The orthoPACE treatments are intended for treating bone conditions that need osteogenesis or calcific joints; conditions causing painful joints; and chronic pain.
More articles on devices:
Medtronic CEO Omar Ishrak: 5 key quotes for the coming year
Global orthopedic devices market to surpass $53B by 2024 — 12 observations
Medtronic reports 5% Q4 revenue growth: 5 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
